Lipopeptide-containing fat-dissolving product, and preparation method therefor and use thereof
By using lipopeptides, especially surfactant, as the active ingredient of lipolytic needles, the pain and side effects of existing lipolytic needles have been solved, safer and more effective lipolytic effect have been achieved, and the lipolytic needles have been improved. Security and willingness to use.
Patent Information
- Application Number
- PCT/CN2024/100671
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-21
- Filing Date
- 2024-06-21
- Publication Date
- 2024-12-26
AI Technical Summary
The existing lipolysis needles use sodium deoxycholate as the active ingredient, which has problems such as pain, great side effects, unstable storage, and the treatment effect is not obvious, resulting in low consumer willingness to use.
Lipopeptides are used as lipolytic active substances, especially surfactants, as lipolytic components that replace sodium deoxycholate, and reduce pain and side effects through compatibility and biodegradability with aqueous solutions, thereby improving lipolytic effect.
Surfactant, as a lipolytic ingredient, can effectively dissolve fat cells, reduce local fat accumulation, and has less side effects than lipolytic preparations on the market, and is close to the human pH value, reducing pain during injection and improving lipolytic effect.
Smart Images

Figure CN2024100671_26122024_PF_FP_ABST
Abstract
Description
A lipopeptide-containing fat-dissolving product and its preparation method and application
[0001] This application claims priority to the Chinese patent application filed with the Patent Office of China on June 21, 2023, with application number 202310745466.3 and invention name “A lipolytic product containing lipopeptides, its preparation method and application”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present application relates to the field of medical cosmetology, and specifically to a lipopeptide-containing lipolysis product, a preparation method thereof, and an application thereof. Background Art
[0003] Weight loss and slimming have always been areas of focus. Among weight loss and slimming methods, surgical liposuction offers the most significant results, but its drawbacks include significant surgical trauma and a long recovery period. Non-surgical lipolysis, on the other hand, addresses the high risks and long recovery period associated with surgical liposuction, improving customer comfort and safety. Currently, the mainstream non-surgical lipolysis technologies include cryolipolysis, radiofrequency lipolysis, ultrasound lipolysis, and lipolysis injections. Cryolipolysis, radiofrequency lipolysis, and ultrasound lipolysis require specialized equipment, while lipolysis injections do not. They involve the local injection of medication directly into the subcutaneous fat layer to dissolve the adipose tissue. Currently, lipolysis injections are a scarce product. In April 2015, Allergan's Kybella (active ingredient: sodium deoxycholate) became the first lipolysis injection product approved by the US FDA for the removal of excess submental fat (double chin). However, no lipolysis injection products have been approved in China.
[0004] The active ingredient of Kybella lipolysis injection is 1% sodium deoxycholate. The solution also contains 0.9% benzyl alcohol, 0.44% sodium chloride, and inorganic salt components such as sodium hydroxide and phosphate. The pH value is 8.3. Sodium deoxycholate is a chemically synthesized small molecule compound with the same structure as endogenous deoxycholic acid. Some researchers believe that when the pH value of the solution of sodium deoxycholate is lower than 8.2, it will form a precipitate after being placed for a long time for one month. Only when the pH value is greater than 8.2 will no precipitate be produced. Therefore, the pH value of Kybella lipolysis injection preparation is 8.3. However, the normal range of human physiological pH is usually between 7.35-7.45, and when the pH value and osmotic pressure of the injection preparation are different from the normal physiological values of the human body, it will cause pain.
[0005] To address the above issues, patent CN112955125A relates to a dry powder preparation for injection of deoxycholic acid components, which has excellent storage stability and a pH of 8.2 or lower. When dissolved in water for injection, it reduces pain during injection by forming a pH environment closer to that of the human body than conventional injections, and allows sodium deoxycholate to dissolve well in water for injection without forming precipitation.
[0006] Biological cell membranes are composed of a lipid bilayer. The hydrophobic chains of amphiphilic surfactants can embed within the lipid bilayer, destabilizing the cell membrane and causing its breakdown, leading to cell lysis. Cell membrane lipids or cell lysates mix with the surfactant to form micelles, which then attract surrounding macrophages to aggregate and phagocytose them, triggering a tissue inflammatory response. Sodium deoxycholate, an ionic surfactant, dissolves fat by dissolving adipocytes at the injection site. While the clinical efficacy of Kybella lipolysis injections has been demonstrated, clinical applications and market feedback indicate that existing lipolysis injections are ineffective and have certain side effects. Common side effects of sodium deoxycholate lipolysis injections include post-injection inflammation, manifesting as erythema and edema. Repeated inflammatory reactions from multiple injections may lead to fibrosis, occasionally resulting in the development of hard nodules at the injection site, which resolve over weeks to months. Consequently, consumers may avoid lipolysis injections due to dissatisfaction with existing treatments or fear of side effects. If safer and more effective lipolysis injections can be developed, it will greatly increase consumers' willingness to use them and expand new unmet body shaping markets, officially leading body shaping into the era of medical aesthetics and micro-surgery.
[0007] Lipopeptides are composed of fatty acids linked to short linear or circular peptide chains. The differences between this family of structural homologues can be the type, number (7-25) and configuration of amino acids in the peptide fragment, the length (12-17 carbons) and composition of the fatty acid chain, and the different linking groups between the two parts. Lipopeptides are generally produced by the metabolism of Gram-positive bacteria and exhibit a variety of biological activities. In current research, the biological activities exhibited by lipopeptides mainly include: surfactant, emulsifier, antibacterial, antiviral, antitumor, hemolytic, anti-inflammatory, etc., and can be applied in medicine, cosmetics, oil recovery, agriculture, washing, textiles and other fields.
[0008] Currently, the uses of lipopeptides are becoming increasingly widespread. Patent CN103570809B relates to an anti-inflammatory lipopeptide that binds to the TLR2 receptor, inducing the nuclear entry of β-catenin. β-catenin competes with p65 for binding to PPAR-γ, thereby exerting an anti-inflammatory effect. Patent CN111518163A first proposed that lipopeptides have strong anti-COVID-19 activity and can be widely used in topical skin remedies, protective agents, cleansers, personal care products, and other applications to inhibit or kill viruses against the new coronavirus. Similarly, Patent CN111643656A proposes that lipopeptides have broad-spectrum coronavirus membrane fusion inhibitors and their use against HIV. The lipopeptide is a compound obtained by modifying a polypeptide with antiviral activity with a lipophilic compound. Patent CN112679576A relates to a method for preparing an antimicrobial lipopeptide hydrogel and its use in antibacterial and tissue damage repair. The antimicrobial lipopeptide is obtained by coupling the amino acid sequence KKAAA(K)nAAAKK with an aliphatic hydrocarbon acid, where n is an integer from 1 to 4. Patent CN113683673A discloses a lipopeptide based on melittin. This lipopeptide is obtained by coupling a C10-18 fatty acid to the N-terminus of melittin and modifying the C-terminus with amidation. Compared with melittin, it has better inhibition of Gram-positive and Gram-negative bacteria and lower hemolysis. Patent CN113908252A mentions that surfactin can significantly inhibit Propionibacterium acnes and / or Malassezia, and relates to the use of surfactin in the preparation of antimicrobial drugs or cosmetics and its preparation method. It can be seen that the application of lipopeptides has gradually expanded, especially in the field of medicine, which is attracting more and more interest from researchers. However, at present, there is no research showing that lipopeptides are related to fat dissolution.
[0009] In summary, there is an urgent need to develop a lipolysis injection that is both safe and effective in lipolysis.
[0010] Summary of the Invention
[0011] This application aims to solve at least one of the technical problems existing in the prior art or related art.
[0012] To this end, this application uses lipopeptides as lipolytic active substances for the first time in lipolytic drugs and lipolysis processes. This application proves that lipopeptides can replace the existing sodium deoxycholate component as an effective ingredient for lipolysis, effectively reducing local fat accumulation, and at the same time, the side effects are less than those of lipolytic preparations on the market.
[0013] In one aspect, the present application provides the use of lipopeptides in the preparation of fat-soluble products.
[0014] Lipopeptide substances include but are not limited to the following substances, such as surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phosphatidylserine, bacillus antibiotic D, etc.
[0015] Furthermore, the lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15, that is, a β-hydroxy fatty acid whose fatty acyl structure is C14 and / or C15.
[0016] Among them, surfactin (general molecular formula: C 53 H 93 N7O 13 , CAS No.: 24730-31-2) is an anionic biosurfactant produced by the fermentation of Bacillus subtilis, soluble in water and polar organic solvents. The surfactin family is composed of a hydrophilic group of a cyclic heptapeptide and a β-hydroxy fatty acid chain. Its peptide ring contains 7 amino acids, and the acyl structure is C 12 -C 16 The beta-hydroxy fatty acid of the peptide chain is connected to the beta-hydroxyl group on the fatty acid chain through an ester bond to form a ring. It has biodegradability, good biocompatibility, and ultra-low irritation. It is one of the most efficient biosurfactants, and its physical and chemical properties are relatively stable. It is a surfactant and emulsifier with excellent performance. Since surfactin is formed by the connection of fatty acids and cyclic heptapeptides, its degradation products are fatty acids and amino acids, which are harmless to the human body. The present application proves through in vitro cell experiments and in vivo animal experiments that surfactin is an ideal ingredient for injection to eliminate local fat, which has a lipolysis effect comparable to that of sodium deoxycholate and has fewer side effects.
[0017] Although both lipopeptides and sodium deoxycholate are amphipathic substances with hydrophilic and hydrophobic groups, there are great differences between the two. First, the molecular structure and molecular weight are different. Lipopeptides are composed of fatty acids and peptides, while sodium deoxycholate is a type of sodium cholate lacking a hydroxyl group on C7. The molecular weights of the two are about 1036Da and 414Da, respectively. Sodium deoxycholate has a smaller molecular weight and acts on the cell membrane of fat cells in a short period of time. The reaction is more intense and the inflammatory reaction caused is stronger. Moreover, the former can be decomposed and metabolized in the body, while the latter does not decompose in the body. Therefore, the use of lipopeptides as the main active ingredient in fat dissolving in this application is safer and has fewer side effects than the currently commonly used sodium deoxycholate fat dissolving injection.
[0018] Furthermore, the applicant discovered that sodium deoxycholate is difficult to dissolve in water and requires heating to completely dissolve into a transparent, clear fluid. Once the temperature drops to room temperature or below, the aqueous solution of sodium deoxycholate turns into a gel, requiring the pH to be adjusted to above 8.2 to avoid the gel. Therefore, the pH of sodium deoxycholate's lipolysis injection is greater than 8.2. However, the normal physiological pH range of the human body is typically between 7.35 and 7.45, causing pain during injection. Surfactant, on the other hand, is soluble in water, and its aqueous solution is a transparent, clear fluid. Therefore, the pH of the lipolysis injection containing surfactant can be close to the physiological pH of the human body, preventing pain.
[0019] In an optional embodiment, the surfactin (HXRZ) is a laboratory-made sample, and the preparation method can refer to patents CN114214252A and CN105695543B.
[0020] Those skilled in the art can also complete the technical solution of this application by preparing or purchasing surfactin (surfactin-C13, surfactin-C14 and surfactin-C15). The source of surfactin is not further limited here.
[0021] In an optional embodiment, surfactin-C13, surfactin-C14, and surfactin-C15 are surfactins with different acyl structures obtained by liquid phase separation and purification of surfactin (HXRZ). Those skilled in the art can complete the separation and purification process according to actual conditions and existing technologies, and therefore, this application does not impose specific limitations thereon.
[0022] Furthermore, the lipolysis includes dissolving fat cells and / or degrading adipose tissue.
[0023] Furthermore, the lipolytic drug does not break down during the lipolytic process.
[0024] On the other hand, the present application also provides a lipolytic product containing lipopeptides.
[0025] Furthermore, the lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15, that is, a β-hydroxy fatty acid whose fatty acyl structure is C14 and / or C15.
[0026] Furthermore, the content of lipopeptide in the fat-dissolving product is 0.05%-3% by mass; optionally, the content of lipopeptide is 0.1%-1%.
[0027] Optionally, the content of lipopeptides in the fat-dissolving product is 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3% and any percentage in between.
[0028] Those skilled in the art will appreciate that the lipolysis product further includes a pharmaceutically acceptable solvent, carrier, and / or excipient. The solvent may be selected from one or more of water, physiological saline, and PBS. Furthermore, the lipolysis product may further include known functional ingredients such as pH regulators, osmotic pressure regulators, antimicrobial agents, analgesics, and anti-inflammatory agents to enhance the efficacy of the lipolysis product.
[0029] As mentioned above, it is known that sodium deoxycholate easily forms a precipitate under physiological pH conditions of 7.35-7.45. In order to circumvent this disadvantage, the pH value must be adjusted to 8.3, which causes pain during injection. Surfactin does not have this disadvantage. Therefore, those skilled in the art can adjust the pH of the fat-reducing product described in this application as needed, and no specific limitation on the pH range is made here.
[0030] In an optional embodiment, the pH value of the fat-dissolving product is in the range of 7.35-7.45.
[0031] Optionally, the dosage form of the product is selected from injection and / or topical preparation; optionally, the dosage form is injection.
[0032] On the other hand, the present application also provides a method for preparing the above-mentioned liposoluble product, which comprises: uniformly dissolving the lipopeptide in a solvent.
[0033] Furthermore, the lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15, that is, a β-hydroxy fatty acid whose fatty acyl structure is C14 and / or C15.
[0034] More optionally, the content of the lipopeptide is 0.05%-3% by mass; more optionally, the content of the lipopeptide is 0.1%-1%.
[0035] More optionally, the content of the lipopeptide is 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3% and any percentage in between.
[0036] Furthermore, the solvent is selected from one or more of water, physiological saline, and PBS.
[0037] This application has the following beneficial effects:
[0038] 1. This application first discovered that lipopeptides can be directly injected into subcutaneous adipose tissue to destroy the adipocyte membrane, trigger adipocyte rupture, and cause local dissolution of adipose tissue, thereby achieving the purpose of fat dissolution;
[0039] 2. This application demonstrates that, compared to sodium deoxycholate, lipopeptides as the new active ingredient for lipolysis injections have stronger surface activity and lipolysis activity, and their effective dose is lower. Experiments related to the onset time also show that the lipolysis mechanism of surfactin is different from that of sodium deoxycholate;
[0040] 3. The present application uses lipopeptide as a new active ingredient for lipolysis injections, which can overcome the problems of currently available sodium deoxycholate lipolysis injections that are prone to adverse reactions and significant pain during use, making lipolysis injections safer and with fewer side effects, reducing ulceration at the injection site, and being more in line with the human body's pH, thereby reducing pain during the injection process. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The above and / or additional aspects and advantages of the present application will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0042] FIG1 is a statistical diagram of the relative proliferation rate of surfactin cells;
[0043] Figure 2 is a statistical graph of the relative proliferation rate of daptomycin cells;
[0044] FIG3 is a statistical diagram of the relative proliferation rate of sodium deoxycholate cells;
[0045] FIG4 is a diagram showing the effects of surfactin and sodium deoxycholate on mouse adipocytes (observation results of adipocytes under an inverted microscope), with a magnification of 200 times;
[0046] FIG5 is a hematoxylin-eosin stained section of adipose tissue on the left hip of a mouse, at a magnification of 5 times;
[0047] FIG6 is a diagram showing the lipolysis of adipose tissue in transgenic mice by 0.5% surfactin (A) and 1% surfactin (B), with a magnification of 5 times;
[0048] FIG7 is a diagram showing the ulceration of the administration site of mice in the 2% sodium deoxycholate group and the 2% surfactin group, wherein the circled area is the administration site;
[0049] FIG8 is a diagram showing the ulceration of the administration site in mice in the 1% sodium deoxycholate group and the 1% surfactin group after two doses of medication, wherein the circled area indicates the administration site;
[0050] FIG9 is a diagram showing the degradation of inguinal fat in mice in the 0.5% surfactin group, wherein the circle marks the administration site;
[0051] FIG10 is a statistical graph of the left inguinal adipose tissue weight (A) and fat coefficient (B) of each group of mice;
[0052] FIG11 shows typical images of hematoxylin-eosin staining of adipose tissue of mice in each group (A, negative control; B, 1% sodium deoxycholate group; C, 1% surfactin group) and statistical analysis results of average adipocyte density (D), where the magnification is 20 times;
[0053] FIG12 is a diagram showing the lysis effect of HXRZ and HXRZ-A, HXRZ-B and HXRZ-C on red blood cells;
[0054] Figure 13 is the HE staining of the pathological sections of adipose tissue in each group (each picture was taken at 200 times magnification, A. blank control group; B. positive control group; C. HXRZ-B high-dose administration group; D. HXRZ-B medium-dose administration group; E. HXRZ-B low-dose administration group; F. HXRZ-C high-dose administration group; G. HXRZ-C medium-dose administration group; H. HXRZ-C low-dose administration group). DETAILED DESCRIPTION
[0055] Technical terms:
[0056] Adipose tissue: is loose connective tissue composed primarily of fat cells. In humans, adipose tissue is located: beneath the skin (subcutaneous fat), around internal organs (visceral fat), in the bone marrow (yellow marrow), between muscles (muscular system), and in the breasts (breast tissue).
[0057] Ulceration: usually refers to skin ulceration, which often occurs when skin problems such as blisters, eczema, boils, etc. occur.
[0058] Topical preparations: Liquid, semisolid, or solid preparations intended for local action.
[0059] In order to more clearly illustrate the overall concept of the present application, the following is a detailed description of the embodiments in conjunction with the accompanying drawings. In the following description, a large number of further details are provided to provide a more thorough understanding of the present application. However, it is obvious to those skilled in the art that the present application can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present application, some technical features well known in the art are not described.
[0060] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions recommended by the manufacturer.
[0061] Among them, surfactin (HXRZ) is a laboratory-made sample, and the preparation method refers to patents CN114214252A and CN105695543B, with a purity of >98.5%; surfactin HXRZ-A is surfactin-C13, a laboratory-made sample, obtained by liquid phase separation and purification of surfactin HXRZ; surfactin HXRZ-B is surfactin-C14, a laboratory-made sample, obtained by liquid phase separation and purification of surfactin HXRZ; surfactin HXRZ-C is surfactin-C15, a laboratory-made sample, obtained by liquid phase separation and purification of surfactin HXRZ.
[0062] Daptomycin was purchased from Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd.; sodium deoxycholate was purchased from Solebao Biotechnology Co., Ltd.; and basal culture medium was purchased from Nanjing KeyGen Biotechnology Development Co., Ltd.
[0063] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased from the market.
[0064] Example 1 Comparison of Surface Activity of Surfactin and Sodium Deoxycholate
[0065] 0.1% surfactant HXRZ solution and sodium deoxycholate solution were prepared in purified water, respectively. These solutions were then diluted to varying concentrations using a stepwise dilution method. The surface tensions at these concentrations were measured using a JZ-200A automatic interfacial tension meter. The results are shown in Table 1.
[0066] Table 1 CMC value determination results
[0067] As shown in Table 1, a 0.05% concentration of surfactin HXRZ can reduce the surface tension of water from 80 mN / m to 33 mN / m, while a 0.1% concentration of sodium deoxycholate can only reduce the surface tension of water from 80 mN / m to 53 mN / m. This indicates that surfactin HXRZ has a stronger surface activity than sodium deoxycholate, meaning that even relatively low concentrations of surfactin HXRZ can form micelles in water, thereby reducing the surface tension of water. Therefore, it can be inferred that when surfactin HXRZ is injected into adipose tissue, it can act on the cell membranes of adipocytes at relatively low concentrations to form micelles, thereby exerting a lipolysis effect.
[0068] Example 2 Comparison of the half-inhibitory concentration (IC50) of surfactin HXRZ, daptomycin and sodium deoxycholate on adipocytes
[0069] The test was conducted according to GB / T 16886.5 Biological evaluation of medical devices Part 5: In vitro cytotoxicity test (GB / T 16886.5-2017 / ISO 10993-5:2009, IDT) and with reference to the method therein. The specific experimental process is as follows:
[0070] 1. Paving
[0071] Mouse adipocyte cell line 3T3-F442A in logarithmic growth phase was used to generate 1×10 5 The cells were seeded in a 96-well plate at a density of cells / mL, with 100 μL per well. The culture medium system was a basal culture medium supplemented with 10% fetal bovine serum. The seeded cells were placed in a carbon dioxide incubator at 37° C. and 5% CO 2 for routine culture for 24 h.
[0072] 2. Sample solution preparation
[0073] Surfactin HXRZ, daptomycin or sodium deoxycholate were first prepared into a 0.5% solution using PBS, sterilized by filtration with a 0.22 μm filter membrane, and then diluted to the final concentration using serum-free cell culture medium for immediate use.
[0074] 3. Adding medicine
[0075] After 24 h of routine culture, the old culture medium was discarded and replaced with 100 μL sample solution for the experimental group and an equal amount of serum-free culture medium for the normal control group (control). At least three parallel wells were used for each level.
[0076] 4. Detection
[0077] After 24 hours of culture, the relative cell proliferation rate was measured using CCK-8. The culture medium was discarded, and 100 μL of CCK-8 diluted 10-fold with serum-free culture medium was added to each well. The cells were placed in a cell culture incubator and incubated for another 2 hours. The absorbance was measured at 450 nm using a microplate reader. The relative proliferation rate (RGR) was calculated as the ratio of the absorbance of the experimental group to that of the normal control group.
[0078] 5. Results
[0079] The results of relative proliferation rate determination of 3T3-F442A cells treated with surfactin HXRZ, daptomycin or sodium deoxycholate are shown in Table 2 .
[0080] Table 2 Relative cell proliferation rate (%)
[0081] Based on the data in Table 2, Figures 1, 2, and 3 were plotted with concentration as the abscissa and relative cell proliferation rate as the ordinate. The half-inhibitory concentrations (IC50s) for surfactin HXRZ, daptomycin, and sodium deoxycholate were 0.0271 mg / mL, 0.1444 mg / mL, and 0.2605 mg / mL, respectively. This indicates that both surfactin HXRZ and daptomycin exhibit some lipolysis activity at the cellular level, and that surfactin HXRZ exhibits superior lipolysis activity to daptomycin and sodium deoxycholate.
[0082] Example 3 Comparison of the onset time of surfactin HXRZ and sodium deoxycholate on adipocytes
[0083] The experimental steps of Example 3 were the same as those of Example 2, except that the drug addition time was 0.5 h, 4 h, and 24 h. The relative proliferation rate of 3T3-F442A cells treated with surfactin HXRZ and sodium deoxycholate for different time periods is shown in Table 3.
[0084] Table 3 Relative cell proliferation rate (%)
[0085] As shown in Table 3, 0.5 mg / mL sodium deoxycholate can completely dissolve adipocytes after being treated for 0.5 h, while 0.08 mg / mL surfactin HXRZ needs to be treated for 24 h to completely dissolve adipocytes.
[0086] Figure 4 shows images of adipocytes treated with 0.08 mg / mL surfactin HXRZ and 0.5 mg / mL sodium deoxycholate for 4 and 24 hours, respectively. As can be clearly seen in Figure 4, compared to the negative control, adipocytes showed almost no intact cell morphology after 24 hours of surfactin HXRZ treatment and 4 and 24 hours of sodium deoxycholate treatment, indicating near-complete cell death.
[0087] It can be seen that compared with sodium deoxycholate, the effective concentration of surfactin HXRZ on adipocytes is lower, but the onset time is longer. It is speculated that the mechanism of action of surfactin HXRZ and sodium deoxycholate in dissolving adipocytes may be different.
[0088] Example 4 Experiment on the degradation of adipose tissue in the buttocks of transgenic obese mice by surfactin HXRZ and sodium deoxycholate
[0089] According to the results of Example 2, the half-inhibitory concentrations (IC50) of surfactin HXRZ and sodium deoxycholate were 0.0271 mg / mL and 0.2605 mg / mL, respectively. Furthermore, since the active ingredient of Kybella lipolysis injection is 1% sodium deoxycholate, the effective concentrations of surfactin HXRZ and sodium deoxycholate in the animal experiments were designed to be 0.1% and 1%, respectively.
[0090] Six-week-old transgenic obese mice (ob / ob) were used as a model. Different drugs were injected into the left buttock fat pad and divided into three groups, with 7-10 mice in each group. Specifically:
[0091] 1) Negative control group: injection of 200 μL of sterile saline;
[0092] 2) 1% sodium deoxycholate group: injection of 200 μL of 1% sodium deoxycholate sterile saline solution;
[0093] 3) 0.1% Surfactant HXRZ group: 200 μL of 0.1% Surfactant HXRZ sterile saline solution was injected.
[0094] The first administration was designated as day 1 of the experiment, followed by administration on days 3 and 5. The mice's condition and the site of administration were regularly observed during the experiment. On day 21, the mice were sacrificed, and adipose tissue from the left buttocks was dissected and removed. The tissue was quickly fixed in adipose tissue fixative and then embedded in paraffin. Adipose tissue was pathologically stained with hematoxylin-eosin and analyzed under a light microscope. The results are shown in Figure 5.
[0095] As shown in Figure 5, observation of hematoxylin-eosin stained adipose tissue sections showed that, compared with the negative control group, both sodium deoxycholate and surfactin HXRZ caused degradation of adipose tissue at the administration site, manifested as irregular morphology of the originally tightly arranged adipocytes, swelling or rupture of the cells, infiltration of inflammatory cells between cells, and formation of new fibrous tissue in the areas where the adipocytes were degraded and cleared.
[0096] In addition, three mice in the 1% sodium deoxycholate group experienced palpable lumps at the injection site, and one mouse experienced ulceration at the injection site. These findings were absent in the surfactin HXRZ group and the negative control group, indicating no adverse reactions in either group.
[0097] Example 5 Experiment on degradation of adipose tissue in transgenic mice with different concentrations of surfactin HXRZ
[0098] In this example, the degradation of adipose tissue in the buttocks of transgenic mice by different concentrations of surfactin HXRZ was further investigated.
[0099] Specifically, 6-week-old transgenic obese mice (ob / ob) were used as a model, with one mouse in each group. 200 μL of 0.5% and 1% surfactin HXRZ saline solution (test sample) were injected into the left buttock fat pad, respectively. The first administration was the first day of the experiment, followed by one administration on the third and fifth days. The condition of the mice and the site of administration were regularly observed during the experiment. On the 21st day of the experiment, the mice were killed, and the adipose tissue of the left buttock of the mice was dissected and removed. It was quickly fixed in adipose tissue fixative and then embedded in paraffin. The adipose tissue was pathologically stained using hematoxylin-eosin staining, and then observed and analyzed under an optical microscope. The results are shown in Figure 6.
[0100] As shown in Figure 6, both 0.5% and 1% surfactin HXRZ caused degradation of mouse adipose tissue. The extent of degradation of adipose tissue in the 1% surfactin HXRZ group was greater than that in the 0.5% surfactin HXRZ group, indicating that the lipolysis activity of surfactin HXRZ is dose-dependent, with higher doses resulting in greater lipolysis.
[0101] Example 6 Preliminary Study on the Degradation Effects of Surfactin HXRZ and Sodium Deoxycholate on Inguinal Adipose Tissue in Mice
[0102] Six-week-old Kunming mice (20-30 g) were used as the model. 200 μL of different drugs were injected subcutaneously at multiple points in the left groin. The specific groups were as follows:
[0103] 1) Negative control group (3 rats): 200 μL sterile saline;
[0104] 2) 1% sodium deoxycholate group (3 rats): 200 μL 1% sodium deoxycholate saline solution;
[0105] 3) 2% sodium deoxycholate group (3 rats): 200 μL 2% sodium deoxycholate saline solution;
[0106] 4) 0.5% surfactin HXRZ group (3 rats): 200 μL 0.5% surfactin HXRZ saline solution;
[0107] 5) 1% surfactin HXRZ group (3 rats): 200 μL 1% surfactin HXRZ saline solution;
[0108] 6) 2% surfactin HXRZ group (3 rats): 200 μL 2% surfactin HXRZ saline solution;
[0109] The drug was administered every 7 days, and the ulceration of the administration site of each mouse was observed during the administration period. On the 21st day of the experiment, the mice were sacrificed, and the degradation of the left inguinal fat tissue was observed after dissection, as shown in Figures 7-9.
[0110] As shown in Figure 7, after two doses, ulceration occurred at the injection site in both the 2% sodium deoxycholate and 2% surfactin HXRZ groups. Ulceration remained unhealed after 7 days, so dosing was terminated. However, the extent of ulceration at the injection site in the 2% surfactin HXRZ group was less severe than in the 2% sodium deoxycholate group.
[0111] As shown in Figure 8, after two doses, ulceration occurred at the injection site in both the 1% surfactin HXRZ and 1% sodium deoxycholate groups. Macroscopically, the ulceration was less severe in the 1% surfactin HXRZ group than in the 1% sodium deoxycholate group. However, the ulcer completely healed after a 7-day dosing interval. Four more doses were administered thereafter, without further ulceration in any of the groups.
[0112] As shown in Figure 9, no ulceration occurred at the dosing site in any of the mice in the 0.5% surfactin HXRZ group throughout the entire dosing period. Dissection of the inguinal adipose tissue at the dosing site after the experiment revealed blurred edges of the dosing-side adipose tissue compared to the undosed side, indicating some degradation.
[0113] Example 7 Study on the Efficacy and Side Effects of Surfactin HXRZ and Sodium Deoxycholate on the Degradation of Inguinal Adipose Tissue in Mice
[0114] In this example, 6-week-old Kunming mice (20-30 g) were used as a model. 200 μL of different drugs were injected subcutaneously at multiple points in the left groin. The specific groups were as follows:
[0115] 1) Negative control group (9 rats): 200 μL sterile saline;
[0116] 2) Sodium deoxycholate group (9 rats): 200 μL 1% sodium deoxycholate sterile saline solution;
[0117] 3) Surfactin HXRZ group (9 rats): 200 μL of 1% surfactin HXRZ sterile saline solution.
[0118] Compared to Example 6, this example modified the dosing interval to include dosing every 14 days. On day 42 of the experiment, mice were sacrificed, and left inguinal adipose tissue was dissected and removed. The tissue was quickly fixed in adipose tissue fixative and then embedded in paraffin. Specific adipose tissue weights and fat fractions are shown in Table 4 and Figure 10. Adipose tissue was pathologically stained using hematoxylin-eosin staining and then observed and analyzed under an optical microscope. Adipocyte density was calculated, and the results are shown in Table 5 and Figure 11.
[0119] Table 4 Left inguinal adipose tissue weight and fat coefficient of each group of mice
[0120] Note: Fat coefficient = (weight of inguinal fat tissue on the administration side / body weight) × 100%
[0121] *Compared with the negative control group, p < 0.05; **Compared with the negative control group, p < 0.01
[0122] As shown in Table 4 and Figure 10, compared with the negative control group, subcutaneous injection of 1% surfactant HXRZ and 1% sodium deoxycholate both caused a significant reduction in inguinal fat tissue in mice, and the effects of the two were comparable, with no significant difference.
[0123] Table 5 Fat cell density of mice in each group
[0124] Note: Adipocyte density = number of adipocytes in each image / adipose tissue area;
[0125] *Compared with the negative control group, p < 0.05
[0126] As shown in Table 5 and Figure 11, the paraffin sections of adipose tissue were stained with hematoxylin and eosin, and the sections were panoramically scanned using 3DHISTECH (Hungary). As well as analysis by Media Cybemetics (USA), it was found that both 1% sodium deoxycholate and 1% surfactin HXRZ degraded the cells of the inguinal adipose tissue of mice, thereby reducing the average cell density of the adipose tissue. As shown in Figure 11, the average adipocyte density of the 1% sodium deoxycholate group and the 1% surfactin HXRZ group was 727.84±56.64 ( The 1% surfactin HXRZ group showed significant differences from the negative control group (868.2±57.02), with the 1% surfactin HXRZ group showing a significant degradation effect on inguinal adipose tissue in mice. This suggests that both surfactin HXRZ and sodium deoxycholate have a significant effect on the degradation of inguinal adipose tissue in mice, with no significant difference between the two groups. Surfactant can be used as a novel active ingredient for lipolysis.
[0127] Furthermore, this application conducted experiments targeting local inflammatory reactions at the administration site induced by surfactin HXRZ and sodium deoxycholate. After each administration, mice in both the surfactin HXRZ and sodium deoxycholate groups experienced local inflammation, manifested as ulceration, subcutaneous nodules, and lumps. Ulceration was used as a marker of severe local inflammation, while subcutaneous nodules and lumps were used as markers of mild local inflammation. Macrophages in pathological sections were stained using F480 immunohistochemical staining, followed by optical microscopic observation and analysis. The specific results are shown in Table 6.
[0128] Table 6 Local inflammation in mice in each group
[0129] As shown in Table 6, except for day 35, the incidence of local inflammation in mice in the 1% surfactin HXRZ group was no higher than that in the 1% sodium deoxycholate group. Furthermore, no mice in the 1% surfactin HXRZ group experienced ulceration at the administration site throughout the entire administration cycle, while some mice in the 1% sodium deoxycholate group experienced ulceration at the administration site after the first administration. This demonstrates that, compared to sodium deoxycholate, the present application demonstrates that the use of surfactin HXRZ as a lipolytic ingredient is safer and has fewer side effects.
[0130] Example 8 Comparison of the efficacy and safety of surfactin-C13, surfactin-C14, and surfactin-C15—toxic effects on adipocytes
[0131] In this example, the effect of fatty acid chain length and surfactin on adipocyte efficacy was further studied, and HXRZ and HXRZ-A, HXRZ-B, and HXRZ-C were used as samples for the experiment. Specifically, surfactin HXRZ-A was surfactin-C13, surfactin HXRZ-B was surfactin-C14, and surfactin HXRZ-C was surfactin-C15.
[0132] 3T3-F442A mouse adipocytes in the logarithmic growth phase were collected and 1×10 5 Cells were seeded in 96-well plates at a density of 100 μL / mL. After 24 h of culture, the culture medium was replaced with 100 μL of culture medium containing different sample concentrations. The blank control group was treated with an equal amount of serum-free culture medium and cultured for another 24 h. The specific concentrations are shown in Table 7. The relative cell proliferation rate was measured using CCK-8. Assuming the blank control was 100%, the relative proliferation rate and half-inhibitory concentration of each group were calculated using the same method as in Example 2.
[0133] As shown in Table 7, the IC values of HXRZ and HXRZ-A, HXRZ-B, and HXRZ-C on adipocytes 50 Gradually decreases, among which the IC of HXRZ-C50 The lowest, about half of HXRZ-A. In other words, the killing effect on fat cells increases with the length of the fatty acid chain, and HXRZ-C is the most toxic to fat cells.
[0134] Table 7 Toxicity of HXRZ and HXRZ-A, HXRZ-B, and HXRZ-C to 3T3-F442A mouse adipocytes
[0135] Note: The values in the cells are the relative proliferation rates of each group when the proliferation rate of the blank control group is 100%. * indicates a significant difference compared with the Control group (p < 0.05); # indicates a significant difference compared with the HXRZ group at the same concentration (p < 0.05); a indicates a significant difference compared with the HXRZ-A group at the same concentration (p < 0.05); b indicates a significant difference compared with the HXRZ-B group at the same concentration (p < 0.05); c indicates a significant difference compared with the HXRZ-C group at the same concentration (p < 0.05)
[0136] Example 9 Comparison of the efficacy and safety of surfactin-C13, surfactin-C14, and surfactin-C15 - erythrocyte lysis
[0137] Prepared sheep red blood cells were added to normal saline to prepare a red blood cell suspension. Sample solutions of fermented surfactant HXRZ, HXRZ-A, HXRZ-B, and HXRZ-C at varying concentrations were prepared using normal saline. 1 mL of sample solution was added to 1 mL of red blood cell suspension and mixed thoroughly. An equal amount of normal saline was added to the control group. The mixture was incubated in a 37°C water bath for 10 minutes. After centrifugation, the supernatant was collected and the OD was measured. 575nm The values, measurement results and specific concentrations are shown in Table 8 and Figure 12.
[0138] Table 8 Lysis effect of HXRZ and HXRZ-A, HXRZ-B, and HXRZ-C on red blood cells
[0139] As shown in Table 8 and Figure 12, HXRZ and HXRZ-A, HXRZ-B, and HXRZ-C began to lyse erythrocytes at concentrations above 0.03125 mg / mL, with almost complete lysis of erythrocytes at 0.25 mg / mL. There was no significant difference in the hemolytic activity of HXRZ-A, HXRZ-B, and HXRZ-C.
[0140] Example 10 Comparison of the efficacy and safety of surfactin-C13, surfactin-C14, and surfactin-C15 - Animal Experiment
[0141] (1) Experimental plan
[0142] Female Kunming mice (7-8 weeks old, weighing 25.55-33.76 g) were sorted by weight from smallest to largest and divided into groups of 7-8 mice using the Latin method. Each cage was numbered on the tail with a marker pen. The groups were as follows: 1) blank control group; 2) positive control group (10 mg / mL sodium deoxycholate); 3) high-dose HXRZ-B group (10 mg / mL); 4) medium-dose HXRZ-B group (5 mg / mL); 5) low-dose HXRZ-B group (1 mg / mL); 6) high-dose HXRZ-C group (10 mg / mL); 7) medium-dose HXRZ-C group (5 mg / mL); and 8) low-dose HXRZ-C group (1 mg / mL).
[0143] Based on the reported dosage of positive drug injections, the subcutaneous injection dose for this study was 10 mg / mL, 200 μL. Subcutaneous injections were performed using a 34-gauge, 1.5 mm long, 0.6 mm inner diameter, 4-gauge needle. Doses were administered sequentially along the right groin from top to bottom. Doses were administered once every 14 days for a total of four doses.
[0144] During the dosing period, the experimental animals in each group were housed under identical conditions and environments, and their eating, drinking, and activity were observed daily. The dosing site of each mouse was observed daily for ulcers, lumps, etc. Two mice in each group were sacrificed and autopsied 14 days after the second dosing. The remaining mice were sacrificed and autopsied 14 days after the fourth dosing.
[0145] (2) Experimental results
[0146] 2.1 Local adverse reactions
[0147] In this example, statistics were collected on the adverse reactions at the administration site of the experimental mice. The statistical results are shown in Table 9. Except for the abnormal adverse reaction of the first administration in the high-dose HXRZ-B group, the incidence of adverse reactions in the positive control group was higher than 60%, and the incidence of adverse reactions in the sample group was lower than 60%.
[0148] Table 9 Incidence of local adverse reactions in mice in each group after administration
[0149] Note: The value in each cell is the percentage (%) of mice with abnormalities at the inoculation site; abnormalities at the inoculation site refer to redness, swelling, dark red scabs, and skin ulcers at the inoculation site; before the third dose, two mice were dissected from each group to observe the interim results of the administration, thus reducing the number of animals in each group.
[0150] 2.2 Changes in adipose tissue at the administration site
[0151] In this example, changes in adipose tissue at the drug-administered site of the experimental mice were statistically analyzed. Specifically, adipose tissue from the inoculated (right) side of the groin was removed, weighed, and recorded. The percentage of adipose tissue relative to body weight on the inoculated side was then calculated for each mouse [(weight of adipose tissue relative to the inoculated side / mouse weight) × 100%]. The experimental results are shown in Table 10. The average wet fat weight and wet fat weight-to-body weight percentage of mice in the positive drug and each drug-administered group were lower than those in the blank control group. The higher the drug concentration, the more pronounced the effect. However, there was no significant difference between the high- and medium-concentration drugs and the positive drug group.
[0152] Table 10 Changes in adipose tissue weight at the administration site
[0153] Note: * indicates comparison between test group and blank control group, *p<0.05, **p<0.01
[0154] The adipose tissue at the administration site was prepared into pathological sections and stained with HE. The results are shown in FIG13 . Each administration group resulted in adipocyte degradation, lipid lake formation, immune cell infiltration, and new connective tissue generation.
[0155] To further analyze the density and distribution of adipocytes, the inoculated side of the adipose tissue was immersed in adipose tissue fixative and stained with hematoxylin and eosin (HE). After imaging, the adipose tissue area in each image was measured using millimeters as the standard unit. The number of adipocytes in each image was counted, and the area of a single adipocyte was calculated as: adipose tissue area / number of adipocytes; adipocyte density = number of adipocytes / adipose tissue area. The statistical results are shown in Table 11. After drug administration, adipose tissue cells were destroyed, cells enlarged, and cell density decreased. After four doses, the adipose tissue at the administration site had been remodeled, forming new connective tissue. The effect was more pronounced with higher drug concentrations, with HXRZ-C showing slightly better results than HXRZ-B, similar to the results for wet fat weight.
[0156] Table 11 Changes in average fat cell density and average fat cell area in pathological sections of each group
[0157] Note: * indicates comparison between test group and blank control group, *p<0.05, **p<0.01
[0158] The foregoing is merely an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application should all be included within the scope of the claims of the present application.
Claims
1. Application of lipopeptides in the preparation of lipolysis products.
2. The use according to claim 1, characterized in that: The lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15.
3. The use according to claim 1, characterized in that: The lipolysis includes dissolving fat cells and / or degrading adipose tissue.
4. A fat-dissolving product containing lipopeptides.
5. The fat dissolving product according to claim 4, characterized in that: The lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15.
6. The fat dissolving product according to claim 4, characterized in that: In terms of mass percentage, the content of lipopeptide in the fat-dissolving product is 0.05%-3%; optionally, the content of lipopeptide is 0.1%-1%.
7. A method for preparing a fat dissolving product as claimed in any one of claims 4 to 6, characterized in that: The method comprises: uniformly dissolving the lipopeptide in a solvent.
8. The method according to claim 7, characterized in that The lipopeptide is a cyclic lipopeptide; optionally, the lipopeptide is selected from one or more of surfactin, iturin, feninterferon, fengyuansu, daptomycin, polymyxin, bacillus antibiotic L, phospholipid inhibitor, and bacillus antibiotic D; more optionally, the lipopeptide is surfactin and / or daptomycin; more optionally, the lipopeptide is surfactin; more optionally, the surfactin is surfactin-C14 and / or surfactin-C15.
9. The method according to claim 7, characterized in that: In terms of mass percentage, the content of the lipopeptide is 0.05%-3%; more optionally, the content of the lipopeptide is 0.1%-1%.
10. The method according to claim 7, characterized in that The solvent is selected from one or more of water, physiological saline and PBS.
Citation Information
Patent Citations
Anti-inflammatory lipopeptide as well as preparation method and application for same
CN103570809B
A method for producing biosurfactants
CN105695543B
Application of lipopeptide compound type in resistance to novel coronavirus
CN111518163A
Application of broad-spectrum CoV (coronavirus) membrane fusion inhibitor and application thereof to resisting of AIDS virus
CN111643656A
Antibacterial lipopeptide, preparation method of antibacterial lipopeptide hydrogel and application thereof
CN112679576A
